Download
1 / 4
40 likes | 45 Vues
The global needle-free drug delivery devices market is expected to grow at a CAGR of 14.5% during the forecast period. The key factor contributing to the growth of the market includes a rising prevalence of chronic diseases such as CVDs and lifestyle-oriented disorders such as diabetes mellitus, obesity, and hypertension.
E N D
Orion Market Research Global Needle Free Drug Delivery Devices Market Size, Share, Growth and Forecast 2019-2025 Request a free sample of our report on Global Needle Free Drug Delivery Devices Market: https://www.omrglobal.com/request-sample/needle-free-drug-delivery-devices-market-size ------------------------------------------------------------------------------------ Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +1 646-755-7667, +91 7803040404
The Global Needle-Free Drug Delivery Devices Market is expected to exhibit remarkable growth during the forecast period. The market for drug delivery devices is expanding continuously as inventors find new approaches to deliver biologics and, cell and gene therapies. The conventional method of delivering drugs to the body includes tablets, syrups and most commonly injections; however, tablets and syrups work slowly and can cause some side effects to the patients. In addition, patients don’t wish to take medications through oral route due to bitter taste of the medications. And injection is painful due to piercing of needle into the body that can even cause mortality if it is not injected properly or if same needle is used repeatedly. A https://www.omrglobal.com/industry-reports/needle-free-drug-delivery-devices-market-size full report of Needle Free Drug Delivery Devices Market is available at: Needlestick injury is also possible if a broken needle is left in the body, and it can cause infections and transmit diseases to human body. Keeping in mind these limitations of the conventional method of drug delivery, technologies have been advanced in the needle-free drug delivery devices industry in order to deliver drugs to patients with no pain. One of the advancements is the needle-free auto and pen injectors that are designed to deliver a single dose of a specific drug. Autoinjectors are easy to use and offer self-administration to the patients. These were designed to combat the hesitation regarding self- administration of needle-based medications. Advancement in auto-injector design helping pharmaceutical companies to market their drugs more effectively by helping patients to comply with their dosage prescriptions. Further, the players operating in the global needle-free drug delivery devices market are establishing collaborations to bring new devices into the market. For instance, In July 2018, PharmaJet and Mundipharma signed an agreement for marketing and distributing Tropis and Stratis needle-free drug- delivery devices of PharmaJet to more than 120 markets across the globe. The devices are designed for vaccine immunizations. This partnership focuses on providing access to this needle-free technology, to more patients, especially in the emerging economies where outbreaks typically occur. To https://www.omrglobal.com/request-sample/needle-free-drug-delivery-devices-market-size know more information, please request a free report sample PharmaJet's portfolio consists of: •Stratis IM/SC (Stratis) for intramuscular or subcutaneous delivery •Tropis ID (Tropis) for intradermal delivery of liquid medicines directly into the skin Further, in October 2017, Takeda Pharmaceutical Co. Ltd. and Portal Instruments established a collaboration for the development and commercialization of Portal’s needle-free drug delivery device for potential use with Takeda’s investigational or approved biologic medicines. The Portal device is potentially used for applications across a wide range of biologic medicines that currently require administration through an injection.
Takeda in its first development program for potentially using this device would be for investigational use with Entyvio (vedolizumab). Entyvio is a monoclonal antibody used for adults living with moderately to severely active ulcerative colitis or Crohn’s disease. This antibody is currently administered through intravenous infusion. A Phase III clinical trial program is currently being in operation to evaluate the efficacy and safety of a subcutaneous formulation of vedolizumab in adults living with moderately to severely active ulcerative colitis or Crohn’s disease. Needle-Free Drug Delivery Devices Market Segmentation By Technology •Inhaler Technology •Jet Injectors •Transdermal Patch Technology •Others Needle-free Technology By Application •Pain Management •Insulin delivery for Diabetes •Vaccines Delivery •Pediatric Injections •Others Applications Visit here to know more about on Global Needle Free Drug Delivery Devices Market Needle-Free Drug Delivery Devices Market – Segment by Region North America •United States •Canada Europe •Germany •United Kingdom •France •Spain •Italy •Rest of Europe
Asia-Pacific •China •Japan •India •Rest of Asia-Pacific Rest of the World •Latin America •Middle East and Africa About Orion Market Research OMR provide global and regional market reports of various domains such as healthcare, energy, IT, chemicals, and automobiles. OMR provide a 360-degree view of the market with parametric analysis, key market insights, key findings, statistical forecasts, competitive landscape, extensive segmentation, key trends, strategic recommendations and detailed company profiles. For More Information, Visit Orion Market Research Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +1 646-755-7667, +91 7803040404 Source: Global Needle Free Drug Delivery Devices Market
